Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 7/2003

01-09-2003

No increased risk of non-Hodgkin's lymphoma with steroids, estrogens and psychotropics (Netherlands)

Authors: Annette B. Beiderbeck, Elizabeth A. Holly, Miriam C.J.M. Sturkenboom, Jan W. Coebergh, Bruno H.Ch. Stricker, Hubert G.M. Leufkens

Published in: Cancer Causes & Control | Issue 7/2003

Login to get access
Metadata
Title
No increased risk of non-Hodgkin's lymphoma with steroids, estrogens and psychotropics (Netherlands)
Authors
Annette B. Beiderbeck
Elizabeth A. Holly
Miriam C.J.M. Sturkenboom
Jan W. Coebergh
Bruno H.Ch. Stricker
Hubert G.M. Leufkens
Publication date
01-09-2003
Publisher
Kluwer Academic Publishers-Plenum Publishers
Published in
Cancer Causes & Control / Issue 7/2003
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1023/A:1025698109991

Other articles of this Issue 7/2003

Cancer Causes & Control 7/2003 Go to the issue

OriginalPaper

Survival analysis of distant prostate cancer by decade (1973–1997) in the Detroit Metropolitan Surveillance, Epidemiology and End Results (SEER) Program Registry: has outcome improved? (United States)

OriginalPaper

Occupation and breast cancer in women 20–44 years of age (United States)

OriginalPaper

A vision for cancer incidence surveillance in the United States

OriginalPaper

Prospective study of serum retinol, β-carotene, β-cryptoxanthin, and lutein/zeaxanthin and esophageal and gastric cancers in China

OriginalPaper

Glycemic index and load and risk of upper aero-digestive tract neoplasms (Italy)

OriginalPaper

Postmenopausal breast cancer risk in relation to sex steroid hormones, prolactin and SHBG (Sweden)
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits